David Heredia, Head of Oncology Department at Punta Médica Hospital, shared a post on X:
“Long-term data from the VISION trial shows:
Tepotinib offers durable responses in METex14 skipping NSCLC.
- ORR: 51–57%
- PFS: ~6–8.5 months
- OS: ~20–22 months
- Liquid biopsy effective for detection”
Title: Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer
Authors: Paul K. Paik, Wade T. Iams, Hatim Husain, Richard M. O’Hara, Jr, Emmanuel Adewusi, Xiuning Le
You can read the Full Article on Cancer Treatment Reviews.
More posts featuring David Heredia on OncoDaily.